-123-

## WE CLAIM:

## 1. The compounds of Formula I:

5

15

20

25

where:

A is  $-CHR^{13}$  or a bond;

R is hydrogen, halo, cyano,  $-C(0)NR^6R^7$ ,  $C_1-C_6$  alkyl,  $C_1-C_4$  alkoxycarbonyl, carboxy, or phenyl optionally substituted with one or two substituents selected from the group consisting of halo,  $C_1-C_4$  alkyl, and  $C_1-C_4$  alkoxy;

 $R^1$  is hydrogen, halo, cyano, carboxamido, formyl, trimethylsilyl, trifluoromethyl, pentafluoroethyl, or  $C_1$ - $C_6$  alkyl;

 $\rm R^2$  and  $\rm R^3$  are independently hydrogen, halo, amino, nitro,  $\rm C_1\text{-}C_4$  alkoxy, cyano, carboxamido,  $\rm -C(0)NR^8R^9$ ,  $\rm -NR^{10}R^{11}$ ,  $\rm -NHC(0)NHR^{14}$ ,  $\rm C_1\text{-}C_4$  alkoxycarbonyl, carboxyl, trifluoromethyl, or  $\rm C_1\text{-}C_6$  alkyl optionally substituted with a substituent selected from the group consisting of  $\rm C_1\text{-}C_4$  alkoxy, hydroxy, phenoxy, and phenyl;

 $R^4$  and  $R^4$ ' are independently hydrogen,  $C_1$ - $C_4$  alkyl, or benzyl; or  $R^4$  and  $R^4$ ' together with the carbon atom to which they are attached form a cyclopropyl moiety;

 $R^5$  is hydrogen,  $C_1-C_4$  alkyl, or benzyl;

 $R^5$ ' is hydrogen, or  $R^5$  and  $R^5$ ' together with the carbon atom to which they are attached form a cyclopropyl moiety;  $R^6$  and  $R^7$  are independently hydrogen or  $C_1$ - $C_4$  alkyl;

-124-

 $R^8$  is hydrogen or  $C_1$ - $C_4$  alkyl;

 $R^9$  is  $C_1$ - $C_8$  alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of carboxy, phenyl, or pyridyl, said phenyl or pyridyl substituent optionally substituted with one or two substituents selected from the group consisting of halo,  $C_1$ - $C_4$  alkyl, or  $C_1$ - $C_4$  alkoxy;

 $R^{10}$  is hydrogen or  $C_1$ - $C_4$  alkyl;

 $R^{11}$  is  $C_1-C_4$  alkyl or  $C_1-C_4$  acyl;

 $R^{12}$  is hydrogen, halo, or  $C_1$ - $C_4$  alkyl;

 $R^{13}$  is hydrogen,  $C_1-C_4$  alkyl, or benzyl;

 $R^{14}$  is hydrogen,  $C_1$ - $C_4$  alkyl, or phenyl optionally substituted with a substituent selected from the group consisting of halo,  $C_1$ - $C_4$  alkyl, and  $C_1$ - $C_4$  alkoxy;

15 or pharmaceutically acceptable acid addition salts thereof.

2. A pharmaceutical formulation which comprises, in association with a pharmaceutically acceptable carrier, diluent or excipient, a compound of Formula I:

20

10

where:

A is  $-CHR^{13}$  or a bond;

R is hydrogen, halo, cyano,  $-C(0)NR^6R^7$ ,  $C_1-C_6$  alkyl,  $C_1-C_4$  alkoxycarbonyl, carboxy, or phenyl optionally substituted with one or two substituents selected from the group consisting of halo,  $C_1-C_4$  alkyl, and  $C_1-C_4$  alkoxy;

20

25

 $\rm R^1$  is hydrogen, halo, cyano, carboxamido, formyl, trimethylsilyl, trifluoromethyl, pentafluoroethyl, or  $\rm C_1\text{--}C_6$  alkyl;

 $\rm R^2$  and  $\rm R^3$  are independently hydrogen, halo, amino, nitro,  $\rm C_1$ - $\rm C_4$  alkoxy, cyano, carboxamido, - $\rm C(O)NR^8R^9$ , - $\rm NR^{10}R^{11}$ , -NHC(O)NHR<sup>14</sup>,  $\rm C_1$ - $\rm C_4$  alkoxycarbonyl, carboxyl, trifluoromethyl, or  $\rm C_1$ - $\rm C_6$  alkyl optionally substituted with a substituent selected from the group consisting of  $\rm C_1$ - $\rm C_4$  alkoxy, hydroxy, phenoxy, and phenyl;

10  $R^4$  and  $R^4$ ' are independently hydrogen,  $C_1$ - $C_4$  alkyl, or benzyl; or  $R^4$  and  $R^4$ ' together with the carbon atom to which they are attached form a cyclopropyl moiety;

 $R^5$  is hydrogen,  $C_1-C_4$  alkyl, or benzyl;

 $R^{5}$ ' is hydrogen, or  $R^{5}$  and  $R^{5}$ ' together with the carbon atom to which they are attached form a cyclopropyl moiety;

 ${\tt R}^6$  and  ${\tt R}^7$  are independently hydrogen or  ${\tt C}_1{\tt -C}_4$  alkyl;

 $R^8$  is hydrogen or  $C_1-C_4$  alkyl;

 $R^9$  is  $C_1$ - $C_8$  alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of carboxy, phenyl, or pyridyl, said phenyl or pyridyl substituent optionally substituted with one or two substituents selected from the group consisting of halo,  $C_1$ - $C_4$  alkyl, or  $C_1$ - $C_4$  alkoxy;

 $R^{10}$  is hydrogen or  $C_1-C_4$  alkyl;

 $R^{11}$  is  $C_1-C_4$  alkyl or  $C_1-C_4$  acyl;

 $R^{12}$  is hydrogen, halo, or  $C_1-C_4$  alkyl;

 $R^{13}$  is hydrogen,  $C_1-C_4$  alkyl, or benzyl;

 $R^{14}$  is hydrogen,  $C_1$ - $C_4$  alkyl, or phenyl optionally substituted with a substituent selected from the group consisting of halo,  $C_1$ - $C_4$  alkyl, and  $C_1$ - $C_4$  alkoxy; or pharmaceutically acceptable acid addition salts thereof.

3. A method for increasing activation of the  $5-\mathrm{HT}_{2C}$  receptor in mammals, comprising administering to a mammal in

need of such activation a pharmaceutically effective amount of a compound of Formula I:

5 where:

10

A is  $-CHR^{13}$ - or a bond;

R is hydrogen, halo, cyano,  $-C(0)NR^6R^7$ ,  $C_1-C_6$  alkyl,  $C_1-C_4$  alkoxycarbonyl, carboxy, or phenyl optionally substituted with one or two substituents selected from the group consisting of halo,  $C_1-C_4$  alkyl, and  $C_1-C_4$  alkoxy;

 $\rm R^1$  is hydrogen, halo, cyano, carboxamido, formyl, trimethylsilyl, trifluoromethyl, pentafluoroethyl, or  $\rm C_1\text{-}C_6$  alkyl;

 $R^2$  and  $R^3$  are independently hydrogen, halo, amino, nitro,  $C_1$ - $C_4$  alkoxy, cyano, carboxamido, - $C(0)NR^8R^9$ , - $NR^{10}R^{11}$ , - $NHC(0)NHR^{14}$ ,  $C_1$ - $C_4$  alkoxycarbonyl, carboxyl, trifluoromethyl, or  $C_1$ - $C_6$  alkyl optionally substituted with a substituent selected from the group consisting of  $C_1$ - $C_4$  alkoxy, hydroxy, phenoxy, and phenyl;

20  $R^4$  and  $R^4$ ' are independently hydrogen,  $C_1$ - $C_4$  alkyl, or benzyl; or  $R^4$  and  $R^4$ ' together with the carbon atom to which they are attached form a cyclopropyl moiety;

 $R^5$  is hydrogen,  $C_1-C_4$  alkyl, or benzyl;

 $R^5$ ' is hydrogen, or  $R^5$  and  $R^5$ ' together with the carbon atom to which they are attached form a cyclopropyl moiety;  $R^6$  and  $R^7$  are independently hydrogen or  $C_1$ - $C_4$  alkyl;  $R^8$  is hydrogen or  $C_1$ - $C_4$  alkyl;

-127-

 $R^9$  is  $C_1$ - $C_8$  alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of carboxy, phenyl, or pyridyl, said phenyl or pyridyl substituent optionally substituted with one or two substituents selected from the group consisting of halo,  $C_1$ - $C_4$  alkyl, or  $C_1$ - $C_4$  alkoxy;

 $R^{10}$  is hydrogen or  $C_1-C_4$  alkyl;

 $R^{11}$  is  $C_1-C_4$  alkyl or  $C_1-C_4$  acyl;

 $R^{12}$  is hydrogen, halo, or  $C_1-C_4$  alkyl;

 $R^{13}$  is hydrogen,  $C_1-C_4$  alkyl, or benzyl;

 $$\rm R^{14}$  is hydrogen,  $\rm C_{1}\text{--}C_{4}$  alkyl, or phenyl optionally substituted with a substituent selected from the group consisting of halo,  $\rm C_{1}\text{--}C_{4}$  alkyl, and  $\rm C_{1}\text{--}C_{4}$  alkoxy; or pharmaceutically acceptable acid addition salts thereof.

15

10

5

4. A method for the treatment of obesity in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I:

20

where:

A is  $-CHR^{13}$  or a bond;

R is hydrogen, halo, cyano,  $-C(0)NR^6R^7$ ,  $C_1-C_6$  alkyl,  $C_1-C_4$  alkoxycarbonyl, carboxy, or phenyl optionally substituted with one or two substituents selected from the group consisting of halo,  $C_1-C_4$  alkyl, and  $C_1-C_4$  alkoxy;

-128-

 $\rm R^1$  is hydrogen, halo, cyano, carboxamido, formyl, trimethylsilyl, trifluoromethyl, pentafluoroethyl, or  $\rm C_1-C_6$  alkyl;

 $R^2$  and  $R^3$  are independently hydrogen, halo, amino, nitro,  $C_1$ - $C_4$  alkoxy, cyano, carboxamido, - $C(0)NR^8R^9$ , - $NR^{10}R^{11}$ , - $NHC(0)NHR^{14}$ ,  $C_1$ - $C_4$  alkoxycarbonyl, carboxyl, trifluoromethyl, or  $C_1$ - $C_6$  alkyl optionally substituted with a substituent selected from the group consisting of  $C_1$ - $C_4$  alkoxy, hydroxy, phenoxy, and phenyl;

10  $R^4$  and  $R^4$ ' are independently hydrogen,  $C_1$ - $C_4$  alkyl, or benzyl; or  $R^4$  and  $R^4$ ' together with the carbon atom to which they are attached form a cyclopropyl moiety;

 $R^5$  is hydrogen,  $C_1-C_4$  alkyl, or benzyl;

 $R^{5}$ ' is hydrogen, or  $R^{5}$  and  $R^{5}$ ' together with the carbon atom to which they are attached form a cyclopropyl moiety;

 $R^6$  and  $R^7$  are independently hydrogen or  $C_1-C_4$  alkyl;

 $R^8$  is hydrogen or  $C_1-C_4$  alkyl;

5

20

25

30

 $R^9$  is  $C_1$ - $C_8$  alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of carboxy, phenyl, or pyridyl, said phenyl or pyridyl substituent optionally substituted with one or two substituents selected from the group consisting of halo,  $C_1$ - $C_4$  alkyl, or  $C_1$ - $C_4$  alkoxy;

 $R^{10}$  is hydrogen or  $C_1-C_4$  alkyl;

 $R^{11}$  is  $C_1-C_4$  alkyl or  $C_1-C_4$  acyl;

 $R^{12}$  is hydrogen, halo, or  $C_1-C_4$  alkyl;

 $R^{13}$  is hydrogen,  $C_1-C_4$  alkyl, or benzyl;

 $R^{14}$  is hydrogen,  $C_1$ - $C_4$  alkyl, or phenyl optionally substituted with a substituent selected from the group consisting of halo,  $C_1$ - $C_4$  alkyl, and  $C_1$ - $C_4$  alkoxy; or pharmaceutically acceptable acid addition salts thereof.

5. A method for the treatment of depression in mammals, comprising administering to a mammal in need of

such treatment an effective amount of a compound of Formula I:

5

10

where:

A is  $-CHR^{13}$  or a bond;

R is hydrogen, halo, cyano,  $-C(0)NR^6R^7$ ,  $C_1-C_6$  alkyl,  $C_1-C_4$  alkoxycarbonyl, carboxy, or phenyl optionally substituted with one or two substituents selected from the group consisting of halo,  $C_1-C_4$  alkyl, and  $C_1-C_4$  alkoxy;

 $\rm R^1$  is hydrogen, halo, cyano, carboxamido, formyl, trimethylsilyl, trifluoromethyl, pentafluoroethyl, or  $\rm C_1\text{--}C_6$  alkyl;

15  $R^2$  and  $R^3$  are independently hydrogen, halo, amino, nitro,  $C_1$ - $C_4$  alkoxy, cyano, carboxamido,  $-C(0)NR^8R^9$ ,  $-NR^{10}R^{11}$ ,  $-NHC(0)NHR^{14}$ ,  $C_1$ - $C_4$  alkoxycarbonyl, carboxyl, trifluoromethyl, or  $C_1$ - $C_6$  alkyl optionally substituted with a substituent selected from the group consisting of  $C_1$ - $C_4$  alkoxy, hydroxy, phenoxy, and phenyl;

 $R^4$  and  $R^4$ ' are independently hydrogen,  $C_1$ - $C_4$  alkyl, or benzyl; or  $R^4$  and  $R^4$ ' together with the carbon atom to which they are attached form a cyclopropyl moiety;

 $R^5$  is hydrogen,  $C_1-C_4$  alkyl, or benzyl;

 $R^5$  is hydrogen, or  $R^5$  and  $R^5$  together with the carbon atom to which they are attached form a cyclopropyl moiety;  $R^6$  and  $R^7$  are independently hydrogen or  $C_1$ - $C_4$  alkyl;  $R^8$  is hydrogen or  $C_1$ - $C_4$  alkyl;

-130-

 $R^9$  is  $C_1$ - $C_8$  alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of carboxy, phenyl, or pyridyl, said phenyl or pyridyl substituent optionally substituted with one or two substituents selected from the group consisting of halo,  $C_1$ - $C_4$  alkyl, or  $C_1$ - $C_4$  alkoxy;

 $R^{10}$  is hydrogen or  $C_1-C_4$  alkyl;

 $R^{11}$  is  $C_1-C_4$  alkyl or  $C_1-C_4$  acyl;

 $R^{12}$  is hydrogen, halo, or  $C_1$ - $C_4$  alkyl;

 $R^{13}$  is hydrogen,  $C_1-C_4$  alkyl, or benzyl;

 $R^{14}$  is hydrogen,  $C_1$ - $C_4$  alkyl, or phenyl optionally substituted with a substituent selected from the group consisting of halo,  $C_1$ - $C_4$  alkyl, and  $C_1$ - $C_4$  alkoxy; or pharmaceutically acceptable acid addition salts thereof.

15

10

6. A method of any of Claims 3, 4, or 5 where the mammal is human.